Is Participation in Cancer Phase I Trials Really Therapeutic?

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2016 Sep 21

PMID 27646944

Citations 18

Authors

Jonathan Kimmelman

Affiliations

Soon will be listed here.

Citing Articles

Outcomes Among Racial and Ethnic Minority Patients With Advanced Cancers in Phase 1 Trials: A Meta-Analysis.

Goel S, Negassa A, Ghalib M, Chaudhary I, Desai K, Shah U JAMA Netw Open. 2024; 7(7):e2421485.

PMID: 38990570 PMC: 11240188. DOI: 10.1001/jamanetworkopen.2024.21485.

Decision-making and autonomy among participants in early-phase cancer immunotherapy trials: a qualitative study.

Avery J, Bell J, Baryolay K, Rodin G, Nissim R, Balneaves L BMC Cancer. 2024; 24(1):373.

PMID: 38528488 PMC: 10962144. DOI: 10.1186/s12885-024-12119-7.

Ethical Criteria for Improved Human Subject Protections in Phase I Healthy Volunteer Trials.

Walker R, MacKay D, Waltz M, Lyerly A, Fisher J Ethics Hum Res. 2022; 44(5):2-21.

PMID: 36047278 PMC: 9931499. DOI: 10.1002/eahr.500139.

Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials.

Chihara D, Lin R, Flowers C, Finnigan S, Cordes L, Fukuda Y Lancet. 2022; 400(10351):512-521.

PMID: 35964611 PMC: 9477645. DOI: 10.1016/S0140-6736(22)01390-3.

Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute.

Chihara D, Huang E, Finnigan S, Cordes L, Skorupan N, Fukuda Y J Clin Oncol. 2022; 40(17):1949-1957.

PMID: 35263120 PMC: 9177250. DOI: 10.1200/JCO.21.02190.

References

Horstmann E, McCabe M, Grochow L, Yamamoto S, Rubinstein L, Budd T . Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med. 2005; 352(9):895-904. DOI: 10.1056/NEJMsa042220. View

Ocana A, Amir E, Yeung C, Seruga B, Tannock I . How valid are claims for synergy in published clinical studies?. Ann Oncol. 2012; 23(8):2161-2166. DOI: 10.1093/annonc/mdr608. View

Weber J, Levit L, Adamson P, Bruinooge S, Burris 4th H, Carducci M . American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment. J Clin Oncol. 2014; 33(3):278-84. PMC: 4516884. DOI: 10.1200/JCO.2014.58.2635. View

Schuklenk U, Lowry C . Terminal illness and access to Phase 1 experimental agents, surgeries and devices: reviewing the ethical arguments. Br Med Bull. 2008; 89:7-22. DOI: 10.1093/bmb/ldn048. View

Roberts Jr T, Goulart B, Squitieri L, Stallings S, Halpern E, Chabner B . Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA. 2004; 292(17):2130-40. DOI: 10.1001/jama.292.17.2130. View

Camacho L, Bacik J, Cheung A, Spriggs D . Presentation and subsequent publication rates of phase I oncology clinical trials. Cancer. 2005; 104(7):1497-504. DOI: 10.1002/cncr.21337. View

Chvetzoff G, Tannock I . Placebo effects in oncology. J Natl Cancer Inst. 2003; 95(1):19-29. DOI: 10.1093/jnci/95.1.19. View

London A, Kimmelman J, Emborg M . Research ethics. Beyond access vs. protection in trials of innovative therapies. Science. 2010; 328(5980):829-30. PMC: 4516403. DOI: 10.1126/science.1189369. View

Italiano A, Massard C, Bahleda R, Vataire A, Deutsch E, Magne N . Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol. 2007; 19(4):787-92. DOI: 10.1093/annonc/mdm548. View

10.

Agrawal M, Emanuel E . Ethics of phase 1 oncology studies: reexamining the arguments and data. JAMA. 2003; 290(8):1075-82. DOI: 10.1001/jama.290.8.1075. View

11.

Henderson V, Demko N, Hakala A, MacKinnon N, Federico C, Fergusson D . A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib. Elife. 2015; 4:e08351. PMC: 4600817. DOI: 10.7554/eLife.08351. View

12.

Printz C . Spontaneous regression of melanoma may offer insight into cancer immunology. J Natl Cancer Inst. 2001; 93(14):1047-8. DOI: 10.1093/jnci/93.14.1047. View

13.

Ciani O, Buyse M, Garside R, Peters J, Saad E, Stein K . Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. J Clin Epidemiol. 2015; 68(7):833-42. DOI: 10.1016/j.jclinepi.2015.02.016. View

14.

Sharma S . Avastin saga reveals debate over clinical trial endpoints. J Natl Cancer Inst. 2012; 104(11):800-1. DOI: 10.1093/jnci/djs265. View

15.

Kimmelman J, London A . The structure of clinical translation: efficiency, information, and ethics. Hastings Cent Rep. 2015; 45(2):27-39. DOI: 10.1002/hast.433. View

16.

Begley C, Ellis L . Drug development: Raise standards for preclinical cancer research. Nature. 2012; 483(7391):531-3. DOI: 10.1038/483531a. View

17.

Morgan R, Yang J, Kitano M, Dudley M, Laurencot C, Rosenberg S . Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010; 18(4):843-51. PMC: 2862534. DOI: 10.1038/mt.2010.24. View

18.

Han K, Ren M, Wick W, Abrey L, Das A, Jin J . Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncol. 2013; 16(5):696-706. PMC: 3984546. DOI: 10.1093/neuonc/not236. View

19.

Wall L, Talbot D, Bradbury P, Jodrell D . A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours. Br J Cancer. 2004; 90(4):800-4. PMC: 2410175. DOI: 10.1038/sj.bjc.6601594. View

20.

Chen T, Chute J, Feigal E, Johnson B, Simon R . A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. J Natl Cancer Inst. 2000; 92(19):1601-7. DOI: 10.1093/jnci/92.19.1601. View